EudraVigilance Expert Working Group (EV-EWG) work programme 2025-2026

Summary of opinion: Xofluza, 25/04/2025 Positive

Human medicines European public assessment report (EPAR): Piasky, Crovalimab, Date of authorisation: 22/08/2024, Revision: 2, Status: Authorised

Human medicines European public assessment report (EPAR): Alunbrig, brigatinib, Date of authorisation: 22/11/2018, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Azacitidine Mylan, azacitidine, Date of authorisation: 27/03/2020, Revision: 10, Status: Authorised

Human medicines European public assessment report (EPAR): Elocta, efmoroctocog alfa, Date of authorisation: 18/11/2015, Revision: 15, Status: Authorised

Human medicines European public assessment report (EPAR): RotaTeq, rotavirus vaccine, live, Date of authorisation: 26/06/2006, Revision: 38, Status: Authorised

Summary of opinion: Amvuttra, 25/04/2025 Positive

Summary of opinion: Veklury, 25/04/2025 Positive

Summary of opinion: Calquence, 25/04/2025 Positive